期刊
ANTI-CANCER DRUGS
卷 33, 期 1, 页码 E738-E740出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000001162
关键词
intravenous immunoglobulin; pembrolizumab; programmed cell death ligand-1; toxic epidermal necrolysis
This article reports a case of toxic epidermal necrolysis in a patient with non-small cell lung cancer following the use of pembrolizumab, which was completely resolved through the use of intravenous immunoglobulin.
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presenting a patient with non-small cell lung cancer that developed toxic epidermal necrolysis 3-days following initiation of pembrolizumab. Following high-dose steroid therapy, intravenous immunoglobulin 2 g/kg was initiated and resulted in complete resolution of all his irAEs. To our knowledge, this is the first reported case of total re-epithelialization and resolution of immune checkpoint inhibitor-induced toxic epidermal necrolysis following the use of intravenous immunoglobulin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据